Oct 8 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Australian drugmaker Clinuvel Pharmaceuticals Ltd's CUV.AX treatment for a rare inherited disorder that results in skin damage from exposure to light, the agency said.
The drug, Scenesse, is an under-the-skin implant that treats erythropoietic protoporphyria, a painful disorder that causes the skin to itch, burn, and scar in some rare cases, when exposed to sunlight and some types of artificial light.